|
1
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heymann MF, Lezot F and Heyman D: The
contribution of immune infiltrates and the local microenvironment
in the pathogenesis of osteosarcoma. Cell Immunol. 343:1037112019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gorlick R, Janeway K, Lessnick S, Randall
RL and Marina N; COG Bone Tumor Committee, : Children's oncology
group's 2013 blueprint for research: Bone tumors. Pediatr Blood
Cancer. 60:1009–1015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu KH, Lin RC, Yang JS, Yang WE, Reiter RJ
and Yang SF: Molecular and cellular mechanisms of melatonin in
osteosarcoma. Cells. 8:16182019. View Article : Google Scholar
|
|
6
|
Zhang Y, Cai L, Li D, Lao YH, Liu D, Li M,
Ding J and Chen X: Tumor microenvironment-responsive
hyaluronate-calcium carbonate hybrid nanoparticle enables effective
chemotherapy for primary and advanced osteosarcomas. Nano Res.
11:4806–4822. 2018. View Article : Google Scholar
|
|
7
|
Feng X, Xu W, Li Z, Song W, Ding J and
Chen X: Immunomodulatory nanosystems. Adv Sci (Weinh).
6:19001012019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang J, Li Z, Wang Z, Yu Y, Li D, Li B and
Ding J: Nanomaterials for combinational radio-immuno oncotherapy.
Adv Funct Mater. Oct 7–2020.(Epub ahead of print).
|
|
9
|
Lowe SW and Lin AW: Apoptosis in cancer.
Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhola PD and Letai A: Mitochondria-judges
and executioners of cell death sentences. Mol Cell. 61:695–704.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen G, Wang F, Trachootham D and Huang P:
Preferential killing of cancer cells with mitochondrial dysfunction
by natural compounds. Mitochondrion. 10:614–625. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Y, Yu K, Wang G, Zhang D, Shi C, Ding
Y, Hong D, Zhang D, He H, Sun L, et al: Lanatoside C inhibits cell
proliferation and induces apoptosis through attenuating
Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell.
Biochem Pharmacol. 150:280–292. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Yu K, Hu Y, Su F, Gao Z, Hu T,
Yang Y, Cao X and Qian F: Schisantherin A induces cell apoptosis
through ROS/JNK signaling pathway in human gastric cancer cells.
Biochem Pharmacol. 173:1136732020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ashkenazi A, Fairbrother WJ, Leverson JD
and Souers AJ: From basic apoptosis discoveries to advanced
selective BCL-2 family inhibitors. Nat Rev Drug Discov. 16:273–284.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang YC, Zheng LH, Ma BA, Zhou Y, Zhang
MH, Zhang DZ and Fan QY: Clinical value of signal transducers and
activators of transcription 3 (STAT3) gene expression in human
osteosarcoma. Acta Histochem. 113:402–408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Goldstein D, Crowe PJ and Yang JL:
Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
Anticancer Res. 34:6537–6545. 2014.PubMed/NCBI
|
|
20
|
Goel S, Sahu S, Minz RW, Singh S, Suri D,
Oh YM, Rawat A, Sehgal S and Saikia B: STAT3-mediated
transcriptional regulation of osteopontin in STAT3 loss-of-function
related hyper IgE syndrome. Front Immunol. 9:10802018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang C, Ma K and Li WY: Cinobufagin
suppresses the characteristics of osteosarcoma cancer cells by
inhibiting the IL-6-OPN-STAT3 pathway. Drug Des Devel Ther.
13:4075–4090. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim YM, Yun J, Lee CK, Lee H, Min KR and
Kim Y: Oxyresveratrol and hydroxystilbene compounds. Inhibitory
effect on tyrosinase and mechanism of action. J Biol Chem.
277:16340–16344. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ortiz-Ruiz CV, Ballesta de Los Santos M,
Berna J, Fenoll J, Garcia-Ruiz PA, Tudela J and Garcia-Canovas F:
Kinetic characterization of oxyresveratrol as a tyrosinase
substrate. IUBMB Life. 67:828–836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heo JI, Kim JH, Lee JM, Kho YJ, Lim SS,
Park JB, Kim J, Kim SC and Lee JY: FOXO3a Activation by
oxyresveratrol of Morus bombycis koidzumi extract mediates
antioxidant activity. Anim Cells Syst. 20:39–47. 2016. View Article : Google Scholar
|
|
25
|
Jia YN, Lu HP, Peng YL, Zhang BS, Gong XB,
Su J, Zhou Y, Pan MH and Xu L: Oxyresveratrol prevents
lipopolysaccharide/D-galactosamine-induced acute liver injury in
mice. Int Immunopharmacol. 56:105–112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee HS, Kim DH, Hong JE, Lee JY and Kim
EJ: Oxyresveratrol suppresses lipopolysaccharide-induced
inflammatory responses in murine macrophages. Hum Exp Toxicol.
34:808–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei J, Chen JR, Pais EMA, Wang TY, Miao L,
Li L, Li LY, Qiu F, Hu LM, Gao XM and Fan GW: Oxyresveratrol is a
phytoestrogen exerting anti-inflammatory effects through NF-κB and
estrogen receptor signaling. Inflammation. 40:1285–1296. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sintuyanon N, Phoolcharoen W, Pavasant P
and Sooampon S: Resveratrol demonstrated higher antiproliferative
and antiangiogenic efficacy compared with oxyresveratrol on head
and neck squamous cell carcinoma cell lines. Natural Prod Commun.
12:1781–1784. 2017.
|
|
29
|
Rahman MA, Bishayee K, Sadra A and Huh SO:
Oxyresveratrol activates parallel apoptotic and autophagic cell
death pathways in neuroblastoma cells. Biochim Biophys Acta Gen
Subj. 1861:23–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matencio A, Dhakar NK, Bessone F, Musso G,
Cavalli R, Dianzani C, García-Carmona F, López-Nicolás JM and
Trotta F: Study of oxyresveratrol complexes with insoluble
cyclodextrin based nanosponges: Developing a novel way to obtain
their complexation constants and application in an anticancer
study. Carbohydr Polym. 231:1157632020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JH, Baek SY, Jang EJ, Ku SK, Kim KM,
Ki SH, Kim CE, Park KI, Kim SC and Kim YW: Oxyresveratrol
ameliorates nonalcoholic fatty liver disease by regulating hepatic
lipogenesis and fatty acid oxidation through liver kinase B1 and
AMP-activated protein kinase. Chem Biol Interact. 289:68–74. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tadtong S, Chatsumpun N, Sritularak B,
Jongbunprasert V, Ploypradith P and Likhitwitayawuid K: Effects of
oxyresveratrol and its derivatives on cultured P19-derived neurons.
Trop J Pharm Res. 15:2619–2628. 2016. View Article : Google Scholar
|
|
33
|
Lee HJ, Feng JH, Sim SM, Lim SS, Lee JY
and Suh HW: Effects of resveratrol and oxyresveratrol on
hippocampal cell death induced by kainic acid. Anim Cells Syst
(Seoul). 23:246–252. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duan C, Han J, Zhang C, Wu K and Lin Y:
Inhibition of kidney cancer cell growth by Mulberroside-A is
mediated via mitochondrial mediated apoptosis, inhibition of cell
migration and invasion and targeting EGFR signalling pathway. J
BUON. 24:296–300. 2019.PubMed/NCBI
|
|
35
|
Li ZR, Ma T, Guo YJ, Hu B, Niu SH, Suo FZ,
Du LN, You YH, Kang WT, Liu S, et al: Sanggenon O induced apoptosis
of A549 cells is counterbalanced by protective autophagy. Bioorg
Chem. 87:688–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Che Q, Xiao X, Liu M, Lu Y, Doug X and Liu
S: IL-6 promotes endometrial cancer cells invasion and migration
through signal transducers and activators of transcription 3
signaling pathway. Pathol Res Pract. 215:1523922019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Y, Ren W, Bai Y, Wan L, Sun X, Liu Y,
Xiong W, Zhang YY and Zhou L: Oxyresveratrol prevents murine H22
hepatocellular carcinoma growth and lymph node metastasis via
inhibiting tumor angiogenesis and lymphangiogenesis. J Nat Med.
72:481–492. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang Y, Zhang G, Li C, Wang S, Zhu M, Wang
J, Yue H, Ma X, Zhen Y and Shu X: Metabolic profile and
structure-activity relationship of resveratrol and its analogs in
human bladder cancer cells. Cancer Manag Res. 11:4631–4642. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miwa S, Sugimoto N, Yamamoto N, Shirai T,
Nishida H, Hayashi K, Kimura H, Takeuchi A, Igarashi K, Yachie A
and Tsuchiya H: Caffeine induces apoptosis of osteosarcoma cells by
inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways. Anticancer Res.
32:3643–3649. 2012.PubMed/NCBI
|
|
41
|
Lu K, Wang X, Chen Y, Liang D, Luo H, Long
L, Hu Z and Bao J: Identification of two potential glycogen
synthase kinase 3β inhibitors for the treatment of osteosarcoma.
Acta Biochim Biophys Sin (Shanghai). 50:456–464. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Messerschmitt PJ, Rettew AN, Brookover RE,
Garcia RM, Getty PJ and Greenfield EM: Specific tyrosine kinase
inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop
Relat Res. 466:2168–2175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kumar RM and Fuchs B: Hedgehog signaling
inhibitors as anti-cancer agents in osteosarcoma. Cancers (Basel).
7:784–794. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi
XL and Hoangn BH: The Wnt signaling pathway: Implications for
therapy in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qian H, Huang T, Chen Y, Li X, Gong W,
Jiang G, Zhang W, Cheng S, Li X and Li P: X-linked inhibitor of
apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt
pathway and inhibits invasion in osteosarcoma cells. J Cancer Res
Ther. 14 (Supplement):S648–S655. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li S, Zhang T, Xu W, Ding J, Yin F, Xu J,
Sun W, Wang H, Sun M, Cai Z and Hua Y: Sarcoma-targeting
peptide-decorated polypeptide nanogel intracellularly delivers
shikonin for upregulated osteosarcoma necroptosis and diminished
pulmonary metastasis. Theranostics. 8:1361–1375. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu J, Wang H, Hu Y, Zhang YS, Wen L, Yin
F, Wang Z, Zhang Y, Li S, Miao Y, et al: Inhibition of CaMKIIα
activity enhances antitumor effect of fullerene C60 nanocrystals by
suppression of autophagic degradation. Adv Sci (Weinh).
6:18012332019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xiao X, Zhang Y, Pan W and Chen F:
MiR-139-mediated NOTCH1 regulation is crucial for the inhibition of
osteosarcoma progression caused by resveratrol. Life Sci.
242:1172152020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Peng L and Jiang D: Resveratrol eliminates
cancer stem cells of osteosarcoma by STAT3 pathway inhibition. PLoS
One. 13:e02059182018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L,
Fernández-Luna JL, Nuñez G, et al: Constitutive activation of Stat3
signaling confers resistance to apoptosis in human U266 myeloma
cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kumari N, Dwarakanath BS, Das A and Bhatt
AN: Role of interleukin-6 in cancer progression and therapeutic
resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Minegishi Y, Saito M, Tsuchiya S, Tsuge I,
Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, et al:
Dominant-negative mutations in the DNA-binding domain of STAT3
cause hyper-IgE syndrome. Nature. 448:1058–1062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang F, Van Meter TE, Buettner R, Hedvat
M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, et
al: Sorafenib inhibits signal transducer and activator of
transcription 3 signaling associated with growth arrest and
apoptosis of medulloblastomas. Mol Cancer Ther. 7:3519–3526. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
